Avalon Investment & Advisory’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $29.5M | Sell |
424,938
-10,883
| -2% | -$768K | 0.81% | 39 |
|
|
2022
Q4 | $31.4M | Buy |
435,821
+5,318
| +1% | +$401K | 0.89% | 34 |
|
|
2022
Q3 | $30.6M | Sell |
430,503
-202,474
| -32% | -$14.7M | 0.95% | 37 |
|
|
2022
Q2 | $48.7M | Sell |
632,977
-46,076
| -7% | -$3.51M | 1.37% | 19 |
|
|
2022
Q1 | $49.6M | Buy |
679,053
+277,784
| +69% | +$18.7M | 1.2% | 31 |
|
|
2021
Q4 | $25M | Sell |
401,269
-61,898
| -13% | -$3.63M | 0.62% | 53 |
|
|
2021
Q3 | $27.4M | Sell |
463,167
-15,876
| -3% | -$1.05M | 0.63% | 52 |
|
|
2021
Q2 | $32M | Sell |
479,043
-5,655
| -1% | -$369K | 0.71% | 46 |
|
|
2021
Q1 | $30.6M | Buy |
484,698
+147,784
| +44% | +$9.19M | 0.7% | 49 |
|
|
2020
Q4 | $20.9M | Buy |
336,914
+17,900
| +6% | +$1.1M | 0.43% | 73 |
|
|
2020
Q3 | $19.2M | Sell |
319,014
-6,771
| -2% | -$408K | 0.43% | 71 |
|
|
2020
Q2 | $19.2M | Sell |
325,785
-30,487
| -9% | -$1.82M | 0.44% | 66 |
|
|
2020
Q1 | $19.9M | Sell |
356,272
-3,464
| -1% | -$212K | 0.51% | 58 |
|
|
2019
Q4 | $23.1M | Sell |
359,736
-4,792
| -1% | -$274K | 0.47% | 68 |
|
|
2019
Q3 | $18.5M | Sell |
364,528
-20,964
| -5% | -$985K | 0.41% | 81 |
|
|
2019
Q2 | $17.5M | Buy |
385,492
+379,179
| +6,006% | +$17.7M | 0.39% | 85 |
|
|
2019
Q1 | $301K | Sell |
6,313
-8,676
| -58% | -$432K | 0.01% | 296 |
|
|
2018
Q4 | $779K | Sell |
14,989
-249,934
| -94% | -$13.4M | 0.02% | 248 |
|
|
2018
Q3 | $16.4M | Buy |
264,923
+250,457
| +1,731% | +$14.9M | 0.46% | 71 |
|
|
2018
Q2 | $801K | Sell |
14,466
-1,918
| -12% | -$104K | 0.02% | 269 |
|
|
2018
Q1 | $1.04M | Sell |
16,384
-201
| -1% | -$12.9K | 0.03% | 255 |
|
|
2017
Q4 | $1.02M | Sell |
16,585
-1,071
| -6% | -$67K | 0.03% | 252 |
|
|
2017
Q3 | $1.13M | Sell |
17,656
-1,306
| -7% | -$76.3K | 0.04% | 242 |
|
|
2017
Q2 | $1.06M | Sell |
18,962
-160,290
| -89% | -$8.72M | 0.04% | 256 |
|
|
2017
Q1 | $9.75M | Buy |
179,252
+64,721
| +57% | +$3.55M | 0.33% | 100 |
|
|
2016
Q4 | $6.69M | Sell |
114,531
-11,864
| -9% | -$649K | 0.24% | 113 |
|
|
2016
Q3 | $6.82M | Sell |
126,395
-104,370
| -45% | -$6.7M | 0.26% | 114 |
|
|
2016
Q2 | $17M | Buy |
230,765
+67,835
| +42% | +$4.79M | 0.66% | 54 |
|
|
2016
Q1 | $10.4M | Buy |
+162,930
| New | +$10.3M | 0.45% | 87 |
|
|
2014
Q2 | – | Sell |
-312,352
| Closed | -$16.2M | – | 182 |
|
|
2014
Q1 | $16.2M | Sell |
312,352
-2,960
| -0.9% | -$158K | 0.9% | 33 |
|
|
2013
Q4 | $16.8M | Buy |
315,312
+2,306
| +0.7% | +$117K | 0.94% | 32 |
|
|
2013
Q3 | $14.5M | Sell |
313,006
-2,699
| -0.9% | -$118K | 0.94% | 30 |
|
|
2013
Q2 | $14.1M | Buy |
+315,705
| New | +$13.7M | 0.84% | 36 |
|
Other funds holding BMY
Avalon Investment & Advisory's BMY Position: Q1 2023 in Review
Avalon Investment & Advisory reduced its Bristol-Myers Squibb (BMY) stake by 2.5% in Q1 2023, selling an estimated $768K and leaving 424,938 shares worth $29.5M. The position accounts for 0.81% of the portfolio, ranked #39.
Avalon Investment & Advisory first reported a position in BMY in Q2 2013 and has held it in 33 quarters since. The position peaked at $49.6M in Q1 2022. 2,542 funds tracked by Wall St. Rank hold BMY as of Q1 2023.
- Avalon Investment & Advisory held 424,938 shares of Bristol-Myers Squibb worth $29.5M as of Q1 2023.
- Avalon Investment & Advisory sold 10,883 Bristol-Myers Squibb shares in Q1 2023, an estimated $768K.
- Bristol-Myers Squibb made up 0.81% of Avalon Investment & Advisory's portfolio in Q1 2023, its #39 holding.
- Avalon Investment & Advisory first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 33 quarters since.
- Avalon Investment & Advisory's Bristol-Myers Squibb position peaked at $49.6M in Q1 2022.
- 2,542 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.
Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.